Yassine Alami Idrissi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yassine Alami Idrissi has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Anwaar Saeed
Department of Medicine, Division of Hematology & Medical Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15213, USA
6 shared publications Alina Zatsepina
2 shared publications- Alireza Tojjari
Department of Medicine, Division of Hematology & Medical Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15213, USA
2 shared publications Anwaar Saeed
2 shared publications- Ahmad E. Saeed
School of Medicine, University of Jordan, Amman, Jordan
1 shared publication - Ahmed Habib
Department of Neurosurgery, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
1 shared publication
Latest Publications
- Open Access
- 14 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Longitudinal Albumin–Bilirubin Trajectory and Survival During Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Background and Aims: The albumin–bilirubin (ALBI) score measures hepatic reserve in hepatocellular carcinoma (HCC). We evaluated the association between longitudinal ALBI changes during immune checkpoint inhibitor (ICI) therapy and overall survival (OS), including their prognostic contribution beyond baseline ALBI. Methods: This retrospective cohort included 227 patients receiving ICI‐based therapy. Serial ALBI trajectory was assessable in 217 patients. Cox regression, patient‐clustered time‐dependent analyses, 42‐, 84‐, and 168‐day landmarks, and endpoint sensitivity analyses were performed. Results: Of 227 patients, 217 met the serial‐ALBI criteria (149 deaths in the primary analysis). Non‐Decliner, Slow Decliner, and Rapid Decliner groups numbered 98, 61, and 58; median OS was 24.8, 11.5, and 4.8 months. Rapid Decliner versus Non‐Decliner adjusted hazard ratio (HR) was 4.21 (95% confidence interval [CI] 2.70–6.57) and 4.71 (2.98–7.44) after baseline ALBI adjustment. At day 84 ( n = 185; 123 events), adjusted HR was 2.44 (1.51–3.92). Apparent C‐index increased from 0.601 to 0.643 (approximately 0.04); this modest in‐sample gain was not validated. Conclusions: Worsening longitudinal ALBI was associated with shorter survival in this retrospective HCC cohort, with attenuation in later landmark analyses. The exploratory 180‐day trajectory groups are defined after treatment begins; their Cox HRs summarize associations over follow‐up rather than constant relative hazards. Continuous‐slope estimates were sensitive to extreme observations. Prospective short‐window derivation and independent validation are required before clinical use.
- 14 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Open AccessLongitudinal Albumin–Bilirubin Trajectory and Survival During Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Background and Aims: The albumin–bilirubin (ALBI) score measures hepatic reserve in hepatocellular carcinoma (HCC). We evaluated the association between longitudinal ALBI changes during immune checkpoint inhibitor (ICI) therapy and overall survival (OS), including their prognostic contribution beyond baseline ALBI. Methods: This retrospective cohort included 227 patients receiving ICI‐based therapy. Serial ALBI trajectory was assessable in 217 patients. Cox regression, patient‐clustered time‐dependent analyses, 42‐, 84‐, and 168‐day landmarks, and endpoint sensitivity analyses were performed. Results: Of 227 patients, 217 met the serial‐ALBI criteria (149 deaths in the primary analysis). Non‐Decliner, Slow Decliner, and Rapid Decliner groups numbered 98, 61, and 58; median OS was 24.8, 11.5, and 4.8 months. Rapid Decliner versus Non‐Decliner adjusted hazard ratio (HR) was 4.21 (95% confidence interval [CI] 2.70–6.57) and 4.71 (2.98–7.44) after baseline ALBI adjustment. At day 84 ( n = 185; 123 events), adjusted HR was 2.44 (1.51–3.92). Apparent C‐index increased from 0.601 to 0.643 (approximately 0.04); this modest in‐sample gain was not validated. Conclusions: Worsening longitudinal ALBI was associated with shorter survival in this retrospective HCC cohort, with attenuation in later landmark analyses. The exploratory 180‐day trajectory groups are defined after treatment begins; their Cox HRs summarize associations over follow‐up rather than constant relative hazards. Continuous‐slope estimates were sensitive to extreme observations. Prospective short‐window derivation and independent validation are required before clinical use.
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (1) , 43
Biology before stage in advanced gastric cancer: converting to cure in biomarker-selected patients
Biology before stage in advanced gastric cancer: converting to cure in biomarker-selected patients
- 1 February 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (1) , 43
Open AccessBiology before stage in advanced gastric cancer: converting to cure in biomarker-selected patients
Biology before stage in advanced gastric cancer: converting to cure in biomarker-selected patients
- Open Access
- 1 December 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (6) , 2891-2894
Claudin 18.2 in gastroesophageal adenocarcinoma: prevalence, biomarker associations, and implications for equity
Editorial Claudin 18.2 in gastroesophageal adenocarcinoma: prevalence, biomarker associations, and implications for equity Yassine Alami Idrissi, Alina Zatsepina, Anwaar Saeed
- 1 December 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (6) , 2891-2894
Open AccessClaudin 18.2 in gastroesophageal adenocarcinoma: prevalence, biomarker associations, and implications for equity
Editorial Claudin 18.2 in gastroesophageal adenocarcinoma: prevalence, biomarker associations, and implications for equity Yassine Alami Idrissi, Alina Zatsepina, Anwaar Saeed
- Open Access
- 11 November 2025
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 141, 103046
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation
- 11 November 2025
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 141, 103046
Open AccessCAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation
- Open Access
The Role of ENHO in Pancreatic Adenocarcinoma: A Bioinformatics Approach
Background: Pancreatic adenocarcinoma (PAAD) is an aggressive subtype of pancreatic cancer that is estimated to have a 5-year overall survival rate of only 13%. Most patients present with advanced disease with unpredictable outcomes. The identification of prognostic biomarkers is important to accurately stratify these patients. Methods: We investigated the molecular and survival-related role of ENHO in PAAD by analyzing TGCA mRNA and miRNA data. Survival analysis was conducted using TIMER2.0, “survival”, and “survminer”. Gene set enrichment analysis was conducted using enrichr, while miRNA-mRNA interactions were identified using “multiMiR”. Immune infiltration was assessed using CIBERSORT ABS and ImmuCellAI. Results: We observed that ENHO was strikingly downregulated in PAAD tissues (p = 3.68 × 10−68), and patients with higher ENHO levels enjoyed significantly better overall survival (HR = 0.597; 95% CI: 0.419–0.852; p < 0.01). Pathway analysis showed that genes co-upregulated with ENHO were enriched for insulin secretion and ion channel activity, whereas those co-downregulated were related to epithelial–mesenchymal transition and extracellular matrix remodeling. Higher ENHO also tracked with increased CD8+ T-cell infiltration and correlated positively with PDCD1 and LAG3 but negatively with B7-H3, CD70, and NT5E. Conclusions: Our results point to a protective role for ENHO in pancreatic adenocarcinoma.
Open AccessThe Role of ENHO in Pancreatic Adenocarcinoma: A Bioinformatics Approach
Background: Pancreatic adenocarcinoma (PAAD) is an aggressive subtype of pancreatic cancer that is estimated to have a 5-year overall survival rate of only 13%. Most patients present with advanced disease with unpredictable outcomes. The identification of prognostic biomarkers is important to accurately stratify these patients. Methods: We investigated the molecular and survival-related role of ENHO in PAAD by analyzing TGCA mRNA and miRNA data. Survival analysis was conducted using TIMER2.0, “survival”, and “survminer”. Gene set enrichment analysis was conducted using enrichr, while miRNA-mRNA interactions were identified using “multiMiR”. Immune infiltration was assessed using CIBERSORT ABS and ImmuCellAI. Results: We observed that ENHO was strikingly downregulated in PAAD tissues (p = 3.68 × 10−68), and patients with higher ENHO levels enjoyed significantly better overall survival (HR = 0.597; 95% CI: 0.419–0.852; p < 0.01). Pathway analysis showed that genes co-upregulated with ENHO were enriched for insulin secretion and ion channel activity, whereas those co-downregulated were related to epithelial–mesenchymal transition and extracellular matrix remodeling. Higher ENHO also tracked with increased CD8+ T-cell infiltration and correlated positively with PDCD1 and LAG3 but negatively with B7-H3, CD70, and NT5E. Conclusions: Our results point to a protective role for ENHO in pancreatic adenocarcinoma.
- Open Access
- 1 April 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (2) , 699-710
Safety and efficacy of pemigatinib in patients with cholangiocarcinoma: a systematic review
Background: Cholangiocarcinoma (CCA) is an aggressive bile duct cancer with limited therapeutic options and poor prognosis. pemigatinib, a selective FGFR inhibitor, has emerged as a promising targeted therapy for CCA patients harboring FGFR2 fusions or rearrangements. This systematic review evaluated the safety and efficacy of pemigatinib in this patient population. Methods: A comprehensive systematic review was conducted across PubMed, Scopus, Embase, Cochrane Library, and Web of Science to identify studies investigating pemigatinib in CCA patients. Five studies involving a total of 459 patients met the inclusion criteria. Results: Pemigatinib demonstrated an overall objective response rate (ORR) of 43.2%, with a complete response (CR) achieved in 3% of patients. Stable disease was observed in 36.9% of patients, while 14.9% experienced disease progression. Median progression-free survival (PFS) varied across studies, due to differences in patient cohorts. The most common adverse effects (AEs) included hyperphosphatemia (48%), diarrhea (28.6%), fatigue (33%), and dry eyes (20.1%). Conclusions: This systematic review suggests that pemigatinib has modest therapeutic efficacy in CCA patients, with a considerable proportion achieving disease control. However, the ORR of less than 50% highlights the potential need for combination or sequential therapies to improve outcomes. Close monitoring and management of AEs, particularly hyperphosphatemia, are crucial for optimizing treatment. Further large-scale randomized trials and research are warranted to identify predictive biomarkers and optimize pemigatinib-based treatment strategies for CCA patients with FGFR2 alterations.
- 1 April 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (2) , 699-710
Open AccessSafety and efficacy of pemigatinib in patients with cholangiocarcinoma: a systematic review
Background: Cholangiocarcinoma (CCA) is an aggressive bile duct cancer with limited therapeutic options and poor prognosis. pemigatinib, a selective FGFR inhibitor, has emerged as a promising targeted therapy for CCA patients harboring FGFR2 fusions or rearrangements. This systematic review evaluated the safety and efficacy of pemigatinib in this patient population. Methods: A comprehensive systematic review was conducted across PubMed, Scopus, Embase, Cochrane Library, and Web of Science to identify studies investigating pemigatinib in CCA patients. Five studies involving a total of 459 patients met the inclusion criteria. Results: Pemigatinib demonstrated an overall objective response rate (ORR) of 43.2%, with a complete response (CR) achieved in 3% of patients. Stable disease was observed in 36.9% of patients, while 14.9% experienced disease progression. Median progression-free survival (PFS) varied across studies, due to differences in patient cohorts. The most common adverse effects (AEs) included hyperphosphatemia (48%), diarrhea (28.6%), fatigue (33%), and dry eyes (20.1%). Conclusions: This systematic review suggests that pemigatinib has modest therapeutic efficacy in CCA patients, with a considerable proportion achieving disease control. However, the ORR of less than 50% highlights the potential need for combination or sequential therapies to improve outcomes. Close monitoring and management of AEs, particularly hyperphosphatemia, are crucial for optimizing treatment. Further large-scale randomized trials and research are warranted to identify predictive biomarkers and optimize pemigatinib-based treatment strategies for CCA patients with FGFR2 alterations.
- Open Access
- 3 December 2024
- Published by Elsevier in Cancer Letters
- Vol. 611, 217362
Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2
- 3 December 2024
- Published by Elsevier in Cancer Letters
- Vol. 611, 217362
Open AccessEmerging targets in gastric and pancreatic cancer: Focus on claudin 18.2
- Open Access
- 27 June 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (7) , 646
Uncovering Interoceptive Human Insular Lobe Function through Intraoperative Cortical Stimulation—A Review
The insular cortex, a critical hub in the brain’s sensory, cognitive, and emotional networks, remains an intriguing subject of study. In this article, we discuss its intricate functional neuroanatomy, emphasizing its pivotal role in processing olfactory information. Through concise exploration, we delve into the insula’s diverse connectivity and its involvement in sensory integration, particularly in olfaction. Stimulation studies in humans reveal compelling insights into the insula’s contribution to the perception of smell, hinting at its broader implications for cognitive processing. Additionally, we explore an avenue of research in which studying olfactory processing via insular stimulation could unravel higher-level cognitive processes. This innovative approach could help give a fresh perspective on the interplay between sensory and cognitive domains, offering valuable insights into the neural mechanisms underlying cognition and emotion. In conclusion, future research efforts should emphasize a multidisciplinary approach, combining advanced imaging and surgical techniques to explore the intricate functions of the human insula. Moreover, awake craniotomies could offer a unique opportunity for real-time observation, shedding light on its neural circuitry and contributions to higher-order brain functions. Furthermore, olfaction’s direct cortical projection enables precise exploration of insular function, promising insights into cognitive and emotional processes. This multifaceted approach will deepen our understanding of the insular cortex and its significance in human cognition and emotion.
- 27 June 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (7) , 646
Open AccessUncovering Interoceptive Human Insular Lobe Function through Intraoperative Cortical Stimulation—A Review
The insular cortex, a critical hub in the brain’s sensory, cognitive, and emotional networks, remains an intriguing subject of study. In this article, we discuss its intricate functional neuroanatomy, emphasizing its pivotal role in processing olfactory information. Through concise exploration, we delve into the insula’s diverse connectivity and its involvement in sensory integration, particularly in olfaction. Stimulation studies in humans reveal compelling insights into the insula’s contribution to the perception of smell, hinting at its broader implications for cognitive processing. Additionally, we explore an avenue of research in which studying olfactory processing via insular stimulation could unravel higher-level cognitive processes. This innovative approach could help give a fresh perspective on the interplay between sensory and cognitive domains, offering valuable insights into the neural mechanisms underlying cognition and emotion. In conclusion, future research efforts should emphasize a multidisciplinary approach, combining advanced imaging and surgical techniques to explore the intricate functions of the human insula. Moreover, awake craniotomies could offer a unique opportunity for real-time observation, shedding light on its neural circuitry and contributions to higher-order brain functions. Furthermore, olfaction’s direct cortical projection enables precise exploration of insular function, promising insights into cognitive and emotional processes. This multifaceted approach will deepen our understanding of the insular cortex and its significance in human cognition and emotion.
- 21 January 2024
- Published by Elsevier in Current Problems in Diagnostic Radiology
- Vol. 53 (3) , 399-404
Imaging 3.0: A scoping review
- 21 January 2024
- Published by Elsevier in Current Problems in Diagnostic Radiology
- Vol. 53 (3) , 399-404
Imaging 3.0: A scoping review
- Open Access
- 1 January 2024
- Published by SAGE Publications in Cancer Control
- Vol. 31
Exploring the Impact of the β-Catenin Mutations in Hepatocellular Carcinoma: An In-Depth Review
Liver cancer, primarily hepatocellular carcinoma, represents a major global health issue with significant clinical, economic, and psychological impacts. Its incidence continues to rise, driven by risk factors such as hepatitis B and C infections, nonalcoholic steatohepatitis, and various environmental influences. The Wnt/β-Catenin signaling pathway, frequently dysregulated in HCC, emerges as a promising therapeutic target. Critical genetic alterations, particularly in the CTNNB1 gene, involve mutations at key phosphorylation sites on β-catenin’s N-terminal domain (S33, S37, T41, and S45) and in armadillo repeat domains (K335I and N387 K). These mutations impede β-catenin degradation, enhancing its oncogenic potential. In addition to genetic alterations, molecular and epigenetic mechanisms, including DNA methylation, histone modifications, and noncoding RNAs, further influence β-catenin signaling and tumor progression. However, β-catenin activation alone is insufficient for hepatocarcinogenesis; additional genetic “hits” are required for tumor initiation. Mutations or alterations in genes such as Ras, c-Met, NRF2, and LKB1, when combined with β-catenin activation, significantly contribute to HCC development and progression. Understanding these cooperative mutations provides crucial insights into the disease and reveals potential therapeutic strategies. The complex interplay between genetic variations and the tumor microenvironment, coupled with novel therapeutic approaches targeting the Wnt/β-Catenin pathway, offers promise for improved treatment of HCC. Despite advances, translating preclinical findings into clinical practice remains a challenge. Future research should focus on elucidating how specific β-catenin mutations and additional genetic alterations contribute to HCC pathogenesis, leveraging genetically clengineered mouse models to explore distinct signaling impacts, and identifying downstream targets. Relevant clinical trials will be essential for advancing personalized therapies and enhancing patient outcomes. This review provides a comprehensive analysis of β-Catenin signaling in HCC, highlighting its role in pathogenesis, diagnosis, and therapeutic targeting, and identifies key research directions to improve understanding and clinical outcomes.
- 1 January 2024
- Published by SAGE Publications in Cancer Control
- Vol. 31
Open AccessExploring the Impact of the β-Catenin Mutations in Hepatocellular Carcinoma: An In-Depth Review
Liver cancer, primarily hepatocellular carcinoma, represents a major global health issue with significant clinical, economic, and psychological impacts. Its incidence continues to rise, driven by risk factors such as hepatitis B and C infections, nonalcoholic steatohepatitis, and various environmental influences. The Wnt/β-Catenin signaling pathway, frequently dysregulated in HCC, emerges as a promising therapeutic target. Critical genetic alterations, particularly in the CTNNB1 gene, involve mutations at key phosphorylation sites on β-catenin’s N-terminal domain (S33, S37, T41, and S45) and in armadillo repeat domains (K335I and N387 K). These mutations impede β-catenin degradation, enhancing its oncogenic potential. In addition to genetic alterations, molecular and epigenetic mechanisms, including DNA methylation, histone modifications, and noncoding RNAs, further influence β-catenin signaling and tumor progression. However, β-catenin activation alone is insufficient for hepatocarcinogenesis; additional genetic “hits” are required for tumor initiation. Mutations or alterations in genes such as Ras, c-Met, NRF2, and LKB1, when combined with β-catenin activation, significantly contribute to HCC development and progression. Understanding these cooperative mutations provides crucial insights into the disease and reveals potential therapeutic strategies. The complex interplay between genetic variations and the tumor microenvironment, coupled with novel therapeutic approaches targeting the Wnt/β-Catenin pathway, offers promise for improved treatment of HCC. Despite advances, translating preclinical findings into clinical practice remains a challenge. Future research should focus on elucidating how specific β-catenin mutations and additional genetic alterations contribute to HCC pathogenesis, leveraging genetically clengineered mouse models to explore distinct signaling impacts, and identifying downstream targets. Relevant clinical trials will be essential for advancing personalized therapies and enhancing patient outcomes. This review provides a comprehensive analysis of β-Catenin signaling in HCC, highlighting its role in pathogenesis, diagnosis, and therapeutic targeting, and identifies key research directions to improve understanding and clinical outcomes.